Physician profile
Kindra R Smith
NPI 1083634406
$1,781.79
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.67 · 2020: $263 · 2021: $107 · 2022: $429 · 2023: $581 · 2024: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $958.70 | 2019-2024 | Wegovy |
| Lilly USA, LLC | $180.42 | 2022-2024 | Zepbound, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $169.86 | 2021-2023 | Shingrix, Bexsero |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.99 | 2024 | Caplyta |
| Intra-Sana Laboratories | $114.49 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Exact Sciences Corporation | $68.81 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.06 | 2023-2024 | Xifaxan |
| Vbi Vaccine (Delaware) INC. | $27.41 | 2022-2023 | Prehevbrio |
| Dexcom, INC. | $24.42 | 2023 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $22.89 | 2023 | Tlando, Xyosted, Nocdurna |
| Pfizer INC. | $16.24 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.80 | 2022 | |
| Genentech USA, INC. | $13.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kindra Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.